ライフサイエンスコーパス: pentoxifylline

1 the effect of treatment with prednisolone or pentoxifylline.

2 a group that received both prednisolone and pentoxifylline.

3 eceiving prednisolone; 546 were treated with pentoxifylline.

4 ich was less frequent in the group receiving pentoxifylline.

5 chloride] but not by the TNF-alpha inhibitor pentoxifylline.

6 (1501-S) and the oxidized side chain analog, pentoxifylline.

7 penicillin; 4 patients were not treated with pentoxifylline.

8 -controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as a timed-release formulat

9 mg of prednisolone once a day and 400 mg of pentoxifylline 3 times a day (n=133) for 28 days, or 40

10 Relative to enprofylline 2b, pentoxifylline 35 was equipotent and 1-propylxanthine 3

11 nty-nine patients were randomized to receive pentoxifylline 400 mg p.o. t.i.d. or matching placebo fo

12 treatment with prednisolone (40 mg daily) or pentoxifylline (400 mg 3 times each day) in patients wit

13 Saline or pentoxifylline (5 or 20 mg/kg im) was administered daily

14 Pentoxifylline (50 mg/kg body weight) or an equivalent v

15 2 and were receiving continuous therapy with pentoxifylline 800 mg 3 times a day and ciprofloxacin 50

16 apsing fever were infused intravenously with pentoxifylline 90 min before intramuscular injection of

17 estigated on pulmonary arterial responses to pentoxifylline, acetylcholine, and isoproterenol during

18 Low-dose (but not high-dose) pentoxifylline administration reduced production of some

19 Pentoxifylline administration, however, significantly in

20 o determine whether or not administration of pentoxifylline after trauma-hemorrhagic shock has any sa

21 mortality; low quality evidence showed that pentoxifylline also decreased short-term mortality (RR,

22 failure; in animal models its blockade with pentoxifylline ameliorates AP.

23 lline-matched placebo, a group that received pentoxifylline and a prednisolone-matched placebo, or a

24 Vasodilator responses to pentoxifylline and acetylcholine were not significantly

25 In patients with severe AH, pentoxifylline and corticosteroids (alone and in combina

26 Based on direct and network meta-analysis, pentoxifylline and obeticholic acid improve fibrosis, an

27 ltration rate or creatinine was seen between pentoxifylline and placebo groups at any interval.

28 h alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisol

29 The abilities of pentoxifylline and recombinant interleukin-10 (rIL-10) t

30 Combinations of pentoxifylline and rIL-10 led to additive or synergistic

31 icantly reduced the vasodilator responses to pentoxifylline and to acetylcholine, whereas NG-L-nitro-

32 Inhibitors of TNF-alpha production (GM6001, pentoxifylline) and TNF-alpha Ab's reduced serum and kid

33 Clinical trials with cladibrine, pentoxifylline, and budesonide have failed to demonstrat

34 the perfusion-modifying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate

35 harmacologic interventions (corticosteroids, pentoxifylline, and N-acetylcysteine [NAC], alone or in

36 oderate-quality evidence supports that TZDs, pentoxifylline, and obeticholic acid decrease lobular in

37 h as progestational agents, cyproheptadines, pentoxifylline, and thalidomide may work by down-regulat

38 Prednisolone and pentoxifylline are both recommended for the treatment of

39 Administration of pentoxifylline at 5 mg/kg/day also down regulated the pr

40 Intraperitoneal administration of pentoxifylline before LPS inhibited TNF-alpha synthesis

41 Pentoxifylline consistently inhibited the accumulation o

42 Patients receiving pentoxifylline demonstrated improved AROM, PROM, and mus

43 induced G2 arrest by treatment with the drug pentoxifylline did not abrogate apoptosis.

44 Pentoxifylline did not attenuate this process and had no

45 Pentoxifylline did not improve survival in patients with

46 Pentoxifylline did not prevent clearance of the B. recur

47 present data also suggest that responses to pentoxifylline during increased tone conditions may, in

48 injection of a TNFalpha synthesis inhibitor, pentoxifylline, during skin tumor promotion completely p

49 ately incubated in the sampling syringe with pentoxifylline, erythro-9-(2-hydroxy-3-nonyl) adenine, a

50 Treatment with pentoxifylline failed to prevent fever, increase in puls

51 The pentoxifylline group had fewer intensive care unit admis

52 odestly between baseline and 6 months in the pentoxifylline group, but not in the placebo group, and

53 13% (35 of 260 patients) in the prednisolone-pentoxifylline group.

54 Patients receiving pentoxifylline had no adverse effects.

55 These data show that pentoxifylline has significant vasodilator activity in t

56 odulators, and more recently thalidomide and pentoxifylline have been used to treat BD with varying d

57 s fed the high-protein liquid diet and given pentoxifylline in a dose of 5 mg/kg/day demonstrated imp

58 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.

59 early reports of renal protective effects of pentoxifylline in bone marrow transplant recipients prom

60 The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested

61 Pentoxifylline inhibits expression of TNF-alpha and HIV.

62 After 8 weeks of pentoxifylline intervention, 20 of 23 patients with impa

63 rsus-host disease prophylaxis with steroids, pentoxifylline, intravenous immunoglobulin, and total bo

64 Prednisolone or pentoxifylline is recommended for severe alcoholic hepat

65 one of four groups: a group that received a pentoxifylline-matched placebo and a prednisolone-matche

66 bo, a group that received prednisolone and a pentoxifylline-matched placebo, a group that received pe

67 Emerging data suggest that pentoxifylline may also be beneficial in improving serum

68 ilable in patients with type 1 HRS, although pentoxifylline may be effective to treat HRS in patients

69 A series of analogues of pentoxifylline metabolites were prepared in the purine,

70 of malignant cells with the c-Rel inhibitor pentoxifylline not only reduced c-Rel nuclear translocat

71 tions (prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some

72 , and a study showing the effect of systemic pentoxifylline on ocular blood flow and diabetes.

73 ected alveolar macrophages were treated with pentoxifylline or anti-TNF-alpha antibody.

74 a was attenuated by administration of either pentoxifylline or anti-TNF-alpha serum, and liver injury

75 rticosteroids (alone and in combination with pentoxifylline or NAC) can reduce short-term mortality.

76 e randomized within 72 hours of diagnosis to pentoxifylline or placebo.

77 paring vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or pl

78 nimals given the high dose (20 mg/kg/day) of pentoxifylline (p< .05).

79 Pentoxifylline (PF) has been used in a wide variety of c

80 nical use of the methyl xanthine derivative, pentoxifylline (PF), for the treatment of T cell-depende

81 acebo group, 19% (50 of 258 patients) in the pentoxifylline-placebo group, and 13% (35 of 260 patient

82 postoperative days (POD) 1, 3, 5, and 7; or pentoxifylline pre-reperfusion and at POD 1 to 5.

83 s, 6-month survival was not different in the pentoxifylline-prednisolone and placebo-prednisolone gro

84 onths was not significantly different in the pentoxifylline-prednisolone and the placebo-prednisolone

85 block of JHR was attempted by administering pentoxifylline prior to antibiotic treatment.

86 rats with anticytokine agents, etanercept or pentoxifylline, produced very similar results.

87 Although pentoxifylline produces various beneficial effects follo

88 Pentoxifylline promotes gut ketogenesis following trauma

89 Pentoxifylline (PTF) inhibits synthesis of some cytokine

90 ctive, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addi

91 ategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed

92 Pentoxifylline (PTX) directly decreases lung endothelial

93 Pentoxifylline (PTX) improved the histological features

94 Previous studies have shown that pentoxifylline (PTX) in combination with alpha-tocophero

95 of this study was to compare the effects of pentoxifylline (PTX) versus placebo on the histological

96 We hypothesized that administration of pentoxifylline (PTX), a phosphodiesterase inhibitor know

97 ntiangiogenic potential of an existing drug, pentoxifylline (PTX), which inhibits PKC-dependent activ

98 Pentoxifylline resulted in decreased plasma HIV RNA and

99 oderate-quality evidence supports the use of pentoxifylline (RR, 0.26; 95% CrI: 0.05-1.00) and obetic

100 val [CrI], 0.39-0.73) or in combination with pentoxifylline (RR, 0.53; 95% CrI, 0.36-0.78) or NAC (RR

101 New agents, including pentoxifylline, thalidomide, and infliximab have proved

102 There was no association between pentoxifylline therapy and the risk of serious infection

103 of this study was to evaluate the ability of pentoxifylline to alter gut cytokine production in a rat

104 10 appeared to interfere with the ability of pentoxifylline to block iNOS accumulation.

105 The addition of NAC, but not pentoxifylline, to corticosteroids may be superior to co

106 Thus, pentoxifylline treatment of patients with relapsing feve

107 leukin 6, or interleukin-8 was observed with pentoxifylline treatment.

108 was also inhibited by both dexamethasone and pentoxifylline, two pharmacological agents with potentia

109 The odds ratio for 28-day mortality with pentoxifylline was 1.07 (95% confidence interval [CI], 0

110 medications such as S-adenosylmethionine and pentoxifylline will need further confirmation by additio

111 Pentoxifylline within 72 hours of pSAP is safe; a larger